Tag: Weight Loss

REDEFINE-4 in Context: Widening Gap between NVO and LLY in Obesity Market

Julia Fitzgerald

Feb 25, 2026 | 5 minutes read | Insight Flash

CagriSema Eli Lilly GLP-1 Novo Nordisk Obesity Ozempic Semaglutide Tirzepatide Wegovy Weight Loss Zepbound

REDEFINE-4 in Context: Widening Gap between NVO and LLY in Obesity Market

Novo Nordisk (NVO) shares declined following results from the REDEFINE-4 trial, where CagriSema achieved 23.0% weight loss at 84 weeks versus 25.5% f...

Learn More

Ozempic is changing how we spend money and time, plus what we eat

Public Relations

Dec 1, 2025 | 5 minutes read | News

Ozempic Washington Post Weight Loss

Ozempic is changing how we spend money and time, plus what we eat

...

Learn More

Tag: Weight Loss

REDEFINE-4 in Context: Widening Gap between NVO and LLY in Obesity Market

Ozempic is changing how we spend money and time, plus what we eat

Subscribe